Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of PT-141 and Melanotan II — mechanism, dosing, side effects, legal status, and pricing.
PT-141 (bremelanotide) is an FDA-approved melanocortin receptor agonist used to treat hypoactive sexual desire disorder (HSDD) in premenopausal women. It works centrally in the brain rather than peripherally on the vascular system.
Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) that stimulates melanin production, causing skin darkening. It was originally developed at the University of Arizona for preventing skin cancer via increased tanning, but was never FDA-approved.
PT-141
Melanotan II
Category
Legal Status
Mechanism
Dose Range
Route
Frequency
Dosing Notes
Side Effects
Contraindications
FDA-approved in 2019 under the brand name Vyleesi for HSDD in premenopausal women. Clinical trials demonstrated statistically significant increases in sexual desire and decreases in distress. Off-label use in men has shown mixed results.
Phase 1 and 2 clinical trials demonstrated dose-dependent skin darkening and sexual arousal side effects. It has never progressed to FDA approval due to safety concerns. The related compound PT-141 (bremelanotide) was developed from Melanotan II specifically for sexual dysfunction.
PT-141 (Hormone) and Melanotan II (Cosmetic) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Disclosed Labs